Joyce Bakker

Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

T. D. de Gruijl, K. Jooss, S. Lougheed, 2022, Science Immunology.

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

T. D. de Gruijl, M. Meijerink, H. Scheffer, 2021, Cancers.

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

E. Smit, A. D. de Langen, M. Wondergem, 2023, Oncoimmunology.

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

R. van Hillegersberg, S. Mook, T. D. de Gruijl, 2023, Oncoimmunology.

MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.

F. Lagerwaard, M. Meijerink, H. Scheffer, 2024, The lancet. Gastroenterology & hepatology.

Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.

M. Meijerink, A. Haynes, P. Doan, 2024, BJU international.